Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4465581 | 0.98 | CHKA (0.38) | CHKACHRNB2CHRNA4MAPTHTT | |
| SCHEMBL4468018 | 0.67 | CHKA (0.48) | CHKACHRNB2CHRNA4MAPTHTT | |
| SCHEMBL4467284 | 0.65 | CHKA (0.47) | CHKAMAPTHTTSIGMAR1 | |
| SCHEMBL233233 | 0.65 | HPGD (0.39) | MAPTHTT | |
| SCHEMBL159767 | 0.64 | HPGD (0.42) | MAPTHTTSIGMAR1 | |
| SCHEMBL354103 | 0.62 | SMPD3 (0.40) | CHKAMAPTHTT | |
| SCHEMBL2579053 | 0.61 | CNR2 (0.39) | CHKAMAPTHTT | |
| SCHEMBL20562664 | 0.61 | TDP1 (0.37) | MAPTHTTSIGMAR1 | |
| SCHEMBL20973017 | 0.61 | ALDH1A1 (0.41) | MAPTHTT | |
| SCHEMBL28317769 | 0.61 | HRH3 (0.36) | MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023640-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-113200962-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-08-03 | — | — | CN | disclosed |
| CN-108430977-B | Phenylimidazole compounds | 株式会社大塚制药工场 | 2021-06-08 | — | — | CN | disclosed |
| US-10570117-B2 | Phenylimidazole compound | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3401310-A1 | PHENYLIMIDAZOLE COMPOUND | Otsuka Pharmaceutical Factory, Inc. (JP) | 2018-11-14 | — | — | EP | disclosed |
| CN-108430977-A | Phenylimidazole compounds | 株式会社大塚制药工场 | 2018-08-21 | — | — | CN | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| CN-1250548-C | Novel adenine derivatives | SUMITOMO PHARMA (JP) | 2006-04-12 | — | — | CN | disclosed |
| CN-1512992-A | Novel adenine derivatives | ס����ҩ��ʽ���� | 2004-07-14 | — | — | CN | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570117-B2 | Phenylimidazole compound | LPL, PNLIP, LIPC | CHKA 277/4885CHRNB2 4770/4885CHRNA4 4700/4885 |
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | CHKA 3151/4885CHRNB2 1913/4885CHRNA4 2643/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | CHKA 2614/4885CHRNB2 1383/4885CHRNA4 2162/4885 |
| US-20180354930-A1 | PHENYLIMIDAZOLE COMPOUND | PNLIP, PLIN1, HDAC11 | CHKA 504/4885CHRNB2 4882/4885CHRNA4 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.